Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NewAmsterdam Pharma Co NVNAMS +1.05%45 Current Ratio is 9.03 as of Jun. 2026, which is 4% below its 10-year median of 9.40. GuruFocus rates NAMS with a GF Score™ of 45/100 and a GF Value™ of $10.42 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,410 Biotechnology companies, NewAmsterdam Pharma Co NV ranks better than 76.74% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. NewAmsterdam Pharma Co NV's current ratio for the quarter that ended in Jun. 2026 was 9.03.
NewAmsterdam Pharma Co NV has a current ratio of 9.03. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for NewAmsterdam Pharma Co NV's Current Ratio or its related term are showing as below:
NAMS'
s Current Ratio Range Over the Past 10 Years
Min: 0.72 Med: 9.4 Max: 21.08
Current: 9.03
During the past 6 years, NewAmsterdam Pharma Co NV's highest Current Ratio was 21.08. The lowest was 0.72. And the median was 9.40.
NAMS's Current Ratio is ranked better than 76.74% of 1410
companies
in the Biotechnology industry
Industry Median: 3.87
vs NAMS: 9.03
NewAmsterdam Pharma Co NV (NAS:NAMS) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
NewAmsterdam Pharma Co NV Current Ratio Related Terms
NewAmsterdam Pharma Co NV Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NAMS vs ARQT, IDYA, ALMS: Current Ratio Comparison
For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NewAmsterdam Pharma Co NV Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's Current Ratio distribution charts can be found below:
* The bar in red indicates where NewAmsterdam Pharma Co NV's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NewAmsterdam Pharma Co NV (NAMS) has a Current Ratio of 9.03 as of Jun. 2026. This is near median its historical median of 9.40. Over the past decade, NewAmsterdam Pharma Co NV's Current Ratio has ranged from 0.72 to 21.08. According to the industry distribution chart, NewAmsterdam Pharma Co NV ranks #328 out of 1410 companies in the Biotechnology industry, placing it in the top 23.3%.
Is NewAmsterdam Pharma Co NV's Current Ratio too high?
NewAmsterdam Pharma Co NV's current Current Ratio of 9.03 is near median its 10-year median of 9.40. Over the past 10 years, this metric has ranged from a low of 0.72 to a high of 21.08. The Biotechnology industry median Current Ratio is 3.87. NewAmsterdam Pharma Co NV's value of 9.03 is 133.3% above this industry median. Based on the distribution chart, NewAmsterdam Pharma Co NV ranks #328 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, NewAmsterdam Pharma Co NV has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NewAmsterdam Pharma Co NV's Current Ratio compare to ARQT and IDYA?
According to the Biotechnology industry distribution chart, NewAmsterdam Pharma Co NV ranks #328 out of 1410 companies for Current Ratio. This places NewAmsterdam Pharma Co NV in the top 23% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.87. NewAmsterdam Pharma Co NV's value of 9.03 is 133.3% above this benchmark. Historically, NewAmsterdam Pharma Co NV's own Current Ratio has ranged from 0.72 to 21.08 over the past decade. While the company's 10-year median is 9.40 vs. the industry median of 3.87, NewAmsterdam Pharma Co NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.87, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NewAmsterdam Pharma Co NV's current Current Ratio of 9.03 is 133.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NewAmsterdam Pharma Co NV's current Current Ratio is 9.03, which is near median its own 10-year median of 9.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewAmsterdam Pharma Co NV stock overvalued right now?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV (NAMS) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.42, compared to a current price of $27.96 — trading 168.3% above its estimated fair value. The current Current Ratio is 9.03, which is near median its 10-year median of 9.40 and 133.3% above the Biotechnology industry median of 3.87. NewAmsterdam Pharma Co NV's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For NewAmsterdam Pharma Co NV (NAMS), the current Current Ratio is 9.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NewAmsterdam Pharma Co NV (NAMS) Overvalued in 2026?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV stock appears to be overvalued.
The current stock price of $27.96 is trading 168.3% above its estimated GF Value™ of $10.42.
GuruFocus considers NewAmsterdam Pharma Co NV to be Significantly Overvalued.
Key valuation signals for NAMS:
Current Ratio: 9.03 (near median its 10-year median of 9.40)
GF Value™: $10.42 vs. price of $27.96 (168.3% above fair value)
Industry Position: 133.3% above the Biotechnology median (#328 of 1410)
No single metric tells the full story. See the NAMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
45GF Score
Get the complete analysis for NAMS
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NAMS has been successfully added to your 
